UBS Maintains Buy on AnaptysBio, Raises Price Target to $90 - AnaptysBio (NASDAQ:ANAB)
Published on March 17, 2026.
The world's largest bank has maintained its position as a Buy on AnaptysBio, raising the price of the company to $90. The move comes as part of a broader trend towards the future of the industry, with the number of potential buyers and potential contributors.
Related Articles
Banking Giant To Bring More Than 300 Jobs To MA With Upcoming Move To South Station Tower
JPMorganChase will relocate to the South Station Tower in 2028, creating over 300 jobs, enhancing Boston's long-term economic stability.
Widows face a hidden tax penalty on a $40 trillion inheritance
Widows face a $40 trillion inheritance tax penalty due to longer life, higher Social Security costs, and reduced income benefits under new tax rules.
China ETFs Suddenly Look Like The War‑Proof Trade of 2026 - iShares MSCI China ETF (NASDAQ:MCHI)
China-focused ETFs, positioned as a potential oil shock hedge, are gaining traction due to strong domestic growth and strategic reserves, amid global tensions.